NCT00482027View on ClinicalTrials.gov

Safety and Immunogenicity Study of tgAAC09, a Gag-PR-RT AAV HIV Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

December 31, 2006

Study Completion Date

January 31, 2007

Conditions
HIV Infection
Interventions
BIOLOGICAL

tgAAC09

one or 2 doses of AAV-2 HIV vaccine (tgAAC09) at 3 dosage levels, dose escalation and dose optimization

Trial Locations (5)

20246

University of Hamburg, Hamburg

53127

Univeristy of Bonn, Bonn

B-2060

SGS Biopharma, Antwerp

B-1000

St. Pierre University Hospital, Brussels

411 026

National AIDS Research Institute, Pune

All Listed Sponsors
collaborator

Targeted Genetics Corporation

INDUSTRY

collaborator

Children's Hospital of Philadelphia

OTHER

collaborator

Nationwide Children's Hospital

OTHER

lead

International AIDS Vaccine Initiative

NETWORK

NCT00482027 - Safety and Immunogenicity Study of tgAAC09, a Gag-PR-RT AAV HIV Vaccine | Biotech Hunter | Biotech Hunter